SUIC Worldwide Holdings Announces Acquisition of Vision Renu; Leadership Changes

What Happened
SUIC Worldwide Holdings Ltd. (SUIC) filed an 8‑K reporting that on July 10, 2026 it entered a share exchange agreement to acquire Vision Renu Corporation and simultaneously reconstituted its board and executive officers. Under the agreement SUIC agreed to issue 30,000,000 shares of SUIC common stock in exchange for Vision Renu equity; the filing states this transaction is intended to be a tax‑free reorganization under Section 368(a). At the effective time the company says Vision Renu’s business was adopted as SUIC’s business and certain directors resigned and new directors/officers were appointed.

Key Details

• Transaction date: July 10, 2026; SUIC to issue 30,000,000 shares as exchange consideration.
• Ownership/structure: Agreement describes SUIC acquiring 51% of Vision Renu; the filing also states Vision Renu “shall be a wholly‑owned subsidiary,” and the Exchange Shares will represent approximately 35% of SUIC’s fully‑diluted common stock.
• Leadership changes: Effective July 10, 2026 Harriette Lo, Han Wei Wang and Yee Wei Tan resigned; Chen King Te was elected Chairman, director and CEO; Kho Jean Jean was elected director and CFO; Dongsheng Zou was appointed director representing Faith & Glory Charity Foundation (reported largest shareholder with 40 million shares).
• Business and operations acquired: Vision Renu develops high‑tech medical devices (notably a Scleral Micro‑Ablation Laser System for presbyopia and a Transcranial Magnetic Stimulation device for depression). Filing cites Taiwan approvals, completed clinical trials, ongoing FDA review for the laser system, government R&D funding and existing orders (over 150 units booked for 2026).
• Financial reporting: The filing includes two years of audited Vision Renu financials; SUIC says pro forma and interim reports will be filed within 70 days as required.

Why It Matters
This filing signals a change in SUIC’s core business and management: the company has acquired medical‑device operations and replaced key directors and executive officers, including a new CEO and CFO. For investors, the material points to watch next are the pro forma financials and interim reports SUIC must file within 70 days (which will show how Vision Renu’s revenues, expenses and liabilities affect SUIC), any dilution or share‑count changes from the 30 million share issuance, and progress on regulatory approvals and commercial orders for Vision Renu’s products.